Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment.
Saved in:
| Title: | Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment. |
|---|---|
| Authors: | Díaz-García, Claudio1,2,3 (AUTHOR), Serrano-Villar, Sergio1,2,4 (AUTHOR), Morales, Alejandro G. García-Ruiz de1,2 (AUTHOR), Güerri-Fernández, Robert2,5,6 (AUTHOR), Pérez-Somarriba, Juncal2,7 (AUTHOR), Palomino, Sonsoles Sánchez2,8 (AUTHOR), Suárez-García, Inés2,9,10 (AUTHOR), Gutiérrez, Cristina Hernández11 (AUTHOR), Juanola, David Dalmau12 (AUTHOR), Moreno, Santiago1,2,3 (AUTHOR), Moreno, Elena1,2 (AUTHOR), Martínez-Sanz, Javier1,2 (AUTHOR) |
| Source: | Open Forum Infectious Diseases. Nov2025, Vol. 12 Issue 11, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
